In Brief: Boehringer Ingelheim
Executive Summary
Boehringer Ingelheim: Glaxo Wellcome announces June 9 that B-I has filed an ANDA for form 1 ranitidine. Glaxo's Zantac, the company says, is form 2 ranitidine with patent protection until 2002. Glaxo "is considering all courses of action open to it." Ciba's Geneva generics subsidiary and the Canadian-owned firm Novopharm previously have filed ANDAs for form 1 ranitidine. Glaxo sued both companies...